; 49 Stat. 1526, chapter 592; 15 U.S.C. 13a et seq. ), and the amendments made by that Act, on drug pricing negotiations. (8) The impact on pharmacies, including pharmacy rebates, pharmacy fees, and dispensing channels. (9) The impact of manufacturer rebates on getting insulin products to market, and the market dynamics and extent to which biosimilar biological product development and competition could increase, or is increasing, the number of biological products approved and available to patients, including by examining barriers to— (A) placement of biosimilar biological products on health insurance formularies; (B) market entry of insulin products in the United States, as compared to other highly developed nations; and (C) patient and provider education around biosimilar biological products. (f) GAO study (1) In general Not later than January 1, 2029, the Comptroller General of the United States shall report to Congress on— (A) pharmacy networks of a selection of group health plans, health insurance issuers, and entities providing pharmacy benefit management services on behalf of such group health plan or group or individual health insurance coverage, including networks that have pharmacies that are affiliated with or in common ownership with group health plans, health insurance issuers, or entities providing pharmacy benefit management services or pharmacy benefit administrative services under group health plan or group or individual health insurance coverage; (B) as it relates to pharmacy networks that include pharmacies affiliated with or in common ownership with plans, issuers, or entities, as described in subparagraph (A)— (i) whether such networks are designed to encourage participants and beneficiaries of a plan or coverage to use such pharmacies over other network pharmacies for specific services or drugs, and if so, the reasons the networks give for encouraging use of such pharmacies